Dr. Elaine Schattner's notes on becoming educated as a patient
Dr. Elaine Schattner's notes on becoming educated as a patient
© Elaine Schattner, 2009, 2022 By : Template Sell.
(in the Style of a Magazine Cover)
If patients knew more:
1. they’d understand more of what doctors say;
2. they’d ask better questions;
3. they’d be more autonomous;
4. they’d make better decisions (ones they’re comfortable with, long-term);
5. they’d spend less money on care they don’t want or need.
If doctors knew more…
If there’s one obvious thing I didn’t learn until I was well into my forties it’s this:
Don’t let a day go by without doing something you feel good about.
This message is not unusual, cryptic or even interesting. It’s simple, really so trite you could find it in most any “how having cancer changed my life” book available in bookstores and on-line.
Why say it again? Everyone knows we should relax and enjoy sunny weekend days like this.
Because it’s a reminder to myself, as much as for some readers and maybe a few fledgling doctors out there. One of my…
A new report from the “Make our Food Safe” project, based at Georgetown University, makes clear that food-borne illnesses – from bacteria, parasites and a few viruses – are ever-present and costly.
The study, authored by Robert Scharff and funded by the Pew Charitable Trusts, finds that food-borne illnesses tally nearly $152 billion per year. This huge sum includes some subjectively-measured expenses like pain, suffering and missed work. Even without those, the toll registers above $100 billion – it’s a big sum, either way.
The main culprits are
There’s a new survivor on TV and she means business.
In the latest episode of The Office, Kathy Bates walked into the Scranton branch of Dundler Mifflen and onto my living room TV screen as Jo Bennett, CEO of Sabre, a fictitious Tallahassee-based company. An assistant and two large canines accompany her as she meets the crew. She’s firm, graying and very much-in-charge.
When the camera gets her alone, in focus, here’s what she has to say:
“I’m Jolene Bennett, Jo for short.
“I’m a breast cancer survivor, close personal friends with Nancy Pelosi, and Truman Capote and I slept with three of the same guys. When I was a little girl I was terrified to fly, and now I have my own pilot’s license.
“I am CEO of Sabre International and I sell the best damn printers and all-in-one machines Korea can make.
“Pleased to meet ya.
There’s promising news on the breast cancer front.
A study published on-line this week in The Journal of Clinical Oncology (JCO) suggests that regular, low-dose aspirin use reduces the risk of recurrence and death from breast cancer among women who’ve had stage I, II or III (non-metastatic) disease.
This is a phenomenal report in three respects:
1. The dramatic results: among women who’ve had breast cancer, regular aspirin use was associated with a reduced risk of recurrence and of death from cancer by more than half;
2. The relevance; these findings might affect millions of women living after breast cancer, today;
3. The cost: aspirin is widely available without patent restriction. Aspirin costs around $5 for 100 tablets, several months’ supply.
This is my first film review, if it is that.
I was tempted to write about Ethan Hawke, hematologist among vampires in Daybreakers, but gore’s not my favorite genre. A mainstream choice would have been Harrison Ford solving the enzyme deficiency of Pompe disease in Extraordinary Measures, but I didn’t get sucked in.
I chose Precious, instead. This luminous movie relates to the practice of medicine everyday, big-time.
“One of the ways that I gained the trust of the family is that I gave them information.” (R. Skloot, a journalist, speaking about her interactions with Henrietta Lacks’ family, Columbia University, 2/2/10)
After a while my oncologist stepped out into the waiting area and guided me to the hall by her office. “The cells are low,” she said. “We’ll have to wait another week, that’s all.”
I knew she was right. But a week seemed like a lifetime to me then….
It was sometime in April, 1988. I was putting a line in an old man with end-stage kidney disease, cancer (maybe), heart failure, bacteria in his blood and no consciousness. Prince was on the radio, loud, by his bedside. If you could call it that – the uncomfortable, curtained compartment didn’t seem like a good place for resting.
This afternoon I found a Tweet from a colleague, a journalist who happens to be a mom in my community:
Tweet from SuSaw:
“RT @JenSinger: Hey, baby. What’s your blood type? Nothing against the Big Pink Machine… http://ow.ly/URkg
As a trained hematologist (blood doc), oncologist and breast cancer survivor, I couldn’t resist checking this out. Here’s what I discovered…
The risks and costs of breast cancer screening are exaggerated and misrepresented in the recent news…. My conclusion is that rather than ditching a life-saving procedure that’s imperfect, we should make sure that all doctors and radiology facilities are up to snuff.
We need to distinguish between errors in the measurement (cancer or not) and errors in decisions that we – patients and doctors – make after upon detecting a premalignant or early-stage malignancy in a woman’s breast.
The risks of radiation from CT scanning will almost certainly add to the current confusion and concerns about the risks of breast cancer screening.
Mammography differs from CT scanning in several important ways:
1. Mammograms involve much less radiation exposure than CT scans.
2. Mammography is well-regulated by the Food and Drug Administration (FDA) and other agencies. The Mammography Quality Standards Act (MQSA) requires…
3. Women who undergo screening mammograms can control when and where they get this procedure. Screening mammograms are elective by nature..
I know what it’s like to get the “red devil” in the veins.
You can learn about Adriamycin, a name brand chemotherapy, on WebMD. Or, if you prefer, you can check on doxorubicin, the generic term, using MedlinePlus, a comprehensive and relatively reliable public venture put forth by the National Library of Medicine and National Institutes of Health. If you’re into organic chemistry, you might want to review the structure of 14-hydroxydaunomycin, an antibiotic and cancer therapy first described 40 years ago…
“Well, well” says the convenience store clerk. “Back for another test?”
“I think the first one was defective. The plus sign looks more like a division symbol, so I remain unconvinced,” states Juno the pregnant teenager.
“Third test today, mama-bear,” notes the clerk.
…”There it is. The little pink plus sign is so unholy,” Juno responds.
She’s pregnant, clearly, and she knows she is.
(see clip from Juno the movie*)
Think of how a statistician might consider Juno’s predicament…
Three key issues have escaped the headlines: 1. The expert panel carried out a careful analysis using data that are, necessarily, old; 2. The recommendations don’t apply to digital mammography; 3. Mammograms are not all the same.
We need to set the bar higher for mammography…
Well, I went ahead and started this blog without a proper introduction. Why was I in such a hurry?
Because I think the media’s getting – and giving – the wrong message on breast cancer screening. When it comes to long, boring medical publications like those published this week in the Annals of Internal Medicine, perhaps it’s not the devil that’s in the details so much as are the facts.
More on that tomorrow –
Smack in the midst of October-is-breast-cancer-awareness-month, the Journal of the American Medical Association published a provocative article with a low-key title: “Rethinking Screening for Breast Cancer and Prostate Cancer.” The authors examined trends in screening, diagnosis and deaths from cancer over two decades, applied theoretical models to the data and found a seemingly disappointing result.
It turns out that standard cancer screening is imperfect.
The subject matters, especially to me. I’m a medical oncologist and a breast cancer survivor, spared seven years ago from a small, infiltrating ductal carcinoma by one radiologist, an expert physician who noted an abnormality on my first screening mammogram…
